Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Changing patent strategies: what will they mean for the industry?

Nature Biotechnology volume 25, pages 867–868 (2007)Cite this article

Could the decline in DNA-based patent applications actually increase the potential for an anticommons effect?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: DNA-based patent applications and issued patents.

References

  1. Heller M.A. & Eisenberg R.S. Science 280, 698–701 (1998).

    Article  CAS  Google Scholar 

  2. Aggarwal, S. Gupta, V. & Bagchi-Sen S . Nat. Biotechnol. 24, 643–651 (2006).

    Article  CAS  Google Scholar 

  3. Lawrence S . Nat. Biotechnol. 22, 930–931 (2004)

    Article  CAS  Google Scholar 

  4. Hopkins M.M. et al. Nat. Biotechnol. 25, 185–187 (2007).

    Article  CAS  Google Scholar 

  5. Pressman L. et al. Nat. Biotechnol. 24, 31–35 (2006).

    Article  CAS  Google Scholar 

  6. FR Doc 01-322, Federal Register 66, No. 4 (Jan. 2001).

  7. Univ. of Rochester v. G.D. Searle & Co., 249 F. Supp. 2d 216 (W.D. N.Y. 2003) (Addendum, Tab B, A0001-33).

  8. Merck KGaA v. Integra Lifesciences I, Ltd., et al., 125 S. Ct. 2372 (2005).

  9. In re Fisher 421 F.3d 1365 (2005).

  10. Allison, J.R. et al. 92 Geo. L. J. 435–477 (2004).

    Google Scholar 

  11. Parchomovsky, G. & Wagner, R.P. 154 U. Pa L. Rev. (2005).

  12. Bessen, J. & Meurer, M. 9 Lewis & Clark L. Rev. (Spring 2005).

  13. Lanjouw, J.O. & Schankerman, M. Rand. J. Econ. 32, 129–151 (2001).

    Article  Google Scholar 

Download references

Acknowledgements

We are grateful for the advice and comments of Margaret Mohrmann, director of the Program in Bioethics in the Center for Bioethics and Humanities at the University of Virginia.

Author information

Authors and Affiliations

  1. Ann E. Mills and Patti M. Tereskerz are at the Program in Ethics and Policy in Health Care at the Center for Biomedical Ethics, University of Virginia School of Medicine, P.O. Box 800758, Charlottesville, Virginia 22908, USA. amh2r@virginia.edu,

    Ann E Mills & Patti M Tereskerz

Authors
  1. Ann E Mills
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patti M Tereskerz
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mills, A., Tereskerz, P. Changing patent strategies: what will they mean for the industry?. Nat Biotechnol 25, 867–868 (2007). https://doi.org/10.1038/nbt0807-867

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0807-867

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing